Radnostix Q2 FY26 net loss widens to $881,997; sale of product drops 27% to $2.67 million
INIS•Q2 FY26 results
Radnostix posted a net loss of $881,997 for the quarter ended June 30, 2026, widening from a net loss of $160,785.
Sales fell 27% to $2.67 million, hit by lost Theranostics sales tied to two voluntary product recalls in January-February 2026.
Liquidity and operations update
The company borrowed $500,000 under a 2026 Promissory Note; capsule inventory was restored in late June, with sales normalized in July.
Profitability and cash position
Gross profit dropped 37% to $1.36 million; gross margin narrowed 8 percentage points to 51%.
Cash and cash equivalents slid 29% to $1.2 million at June 30, 2026; net cash used in operating activities was $686,000.
